🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsRetatrutide and blood pressure — need advice Page 4

Retatrutide and blood pressure — need advice

Dr.RenalNash Wed, Jun 4, 2025 at 8:12 PM 43 replies 2,143 viewsPage 4 of 9
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Jun 6, 2025 at 3:32 AM#16

Adding the clinical framing, because it changes how the question reads.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

References:
[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
34 7paul_denver, TinaHashiRN, robert_kc and 31 others
Reply Quote Save Share Report
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Jun 6, 2025 at 7:20 AM#17

From the other side of the consultation, briefly.

Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically. My endocrinologist recommended it after years of failed interventions.

11 months later: down 57 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

35 8sean_dublin, hannah_MT, Dr.SportsMedIN and 32 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jun 6, 2025 at 11:08 AM#18
sean_dublin said:
Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically.

Same experience, arrived at from the opposite direction. I had assumed I was the exception until I read this.

36 9SkepticalSean, Dr.CardioMD, EndoResFellow and 33 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Jun 6, 2025 at 2:56 PM#19
sean_dublin said:
Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically.

Adding the part of the answer the thread has not reached. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.

Worth separating that from retatrutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

37 10quinn_sf, NurseLeah_Nash, gary_naperville and 34 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 6, 2025 at 6:44 PM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Thread quality here is what the rules are for. Keep it up.

9 7PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 6 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register